OASIS-HAE
23 evidence topics · 5 sources
Objective
Prophylaxis objective
Location and study date
Registered study locations and countries
| Field | Reported value |
|---|---|
| Country | “Belgium” |
| Country | “Bulgaria” |
| Country | “Canada” |
| Country | “Denmark” |
| Country | “France” |
| Country | “Germany” |
| Country | “Israel” |
| Country | “Italy” |
| Country | “Netherlands” |
| Country | “Poland” |
| Country | “Spain” |
| Country | “Turkey (Türkiye)” |
| Country | “United Kingdom” |
| Country | “United States” |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack rate per four weeks as the primary endpoint
Primary clinical endpoint: attack rate over the 24-week treatment period
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Participants |
|---|---|
| Planned total | “84” |
Actual treated populations
| Population | Participants |
|---|---|
| Donidalorsen every four weeks | “45”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “23”View highlighted excerpt for this quote |
| Placebo | “22”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Treatment exposure
| Population | Participants |
|---|---|
| Treated | “90”View highlighted excerpt for this quote |
Baseline characteristics
Efficacy results
Mean attack rate per four weeks: weeks 1–25 in the publication
| Treatment | Attack rate |
|---|---|
| Donidalorsen every four weeks | “0.44”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “1.02”View highlighted excerpt for this quote |
| Placebo | “2.26”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL improvement relative to placebo at week 25: every-four-week regimen
AE-QoL total score: clinically meaningful improvement at week 24
“A greater proportion of the donidalorsen Q4W group achieved clinically meaningful improvement in AE‐QoL total score (≥ 6 points) vs. the placebo group (88.1% vs. 45.0%; odds ratio [OR], 12.2; 95% confidence interval [CI], 2.8 to 54.3; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most Q8W patients (71.4%) also achieved the MCID, but while numerically larger, the difference between the donidalorsen Q8W and placebo groups was not statistically significant (OR, 3.5; 95% CI, 0.8 to 14.3; p = 0.087).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AE-QoL domain scores from baseline to week 24
“Patients reported decreases (improvements) in mean functioning domain scores from 45.2 at baseline to 8.0 at week 24 in the donidalorsen Q4W group and 51.2 to 18.2 in the donidalorsen Q8W group, compared with a decrease from 46.6 to 33.3 in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean fears/shame domain scores improved from 53.2 to 22.3, 54.8 to 27.1, and 57.0 to 51.6 in the donidalorsen Q4W, donidalorsen Q8W, and placebo groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the nutrition domain, patients reported improvements in means from 32.7 to 11.0 (Q4W), 36.9 to 17.6 (Q8W), and 36.4 to 28.5 (placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences in the change in the fatigue/mood domain were observed between the donidalorsen and placebo groups, but scores improved from 41.9 to 28.5 (Q4W), 39.5 to 31.4 (Q8W), and 34.1 to 30.3 (placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema Control Test: change from baseline and disease control at week 24
“Least‐squares mean (LSM) changes from baseline to week 24 in AECT total score were statistically significantly larger in both the Q4W (7.2 points; 95% CI, 5.9 to 8.4) and Q8W donidalorsen (5.2 points; 95% CI, 3.4 to 7.0) groups than in the placebo group (1.2 points; 95% CI, −0.7 to 3.0; Q4W vs. placebo p < 0.001; Q8W vs. placebo p = 0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As reported previously, at week 24, 91% of patients in the donidalorsen Q4W group reported well‐controlled disease vs. 41% of patients in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a significantly greater proportion of patients in the donidalorsen Q8W group (74%) reported well‐controlled disease at week 24 compared with the placebo group (OR vs. placebo, 4.1; 95% CI, 1.2 to 14.4; p = 0.028).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“51% and 48% of patients in the donidalorsen Q4W and Q8W groups, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“reported complete disease control (AECT = 16; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient Global Impression of Severity at week 24
“82% of donidalorsen Q4W patients reporting improvement, that is, less severe disease at week 24 compared with baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the 44% reporting improvements in disease severity in the placebo group (OR, 6.2; 95% CI, 1.4 to 28.2; p = 0.018; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment at week 24
“Mean presenteeism, the percent loss of productivity while at work/school, improved from 25.6% at baseline to 4.0% at week 24 in the donidalorsen Q4W group compared with a decrease from 30.7% to 19.8% in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall work/school impairment decreased from 28.4% to 4.7% in the donidalorsen Q4W group vs. 35.2% to 22.7% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported improvements in the overall activity impairment domain from 35.4% to 10.5% in the donidalorsen Q4W group vs. 34.7% to 21.2% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Numerical improvements from baseline to week 24 were observed in all WPAI domains in the donidalorsen Q8W group, but these changes did not reach significance vs. placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.